

# Melanoma: assessment and management

## Review Questions

*NICE guideline xxxx*

*Review Questions*

*January 2022*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2021. All rights reserved. Subject to [Notice of rights](#).

# Contents

|          |                              |          |
|----------|------------------------------|----------|
| <b>1</b> | <b>Review Questions.....</b> | <b>5</b> |
|----------|------------------------------|----------|

# 1 Review Questions

RQ 1.1 What is the role and optimal timing of genetic testing of the tumour after diagnosis for a person with melanoma?

RQ 2.1 What is the most accurate method of staging melanoma in people preliminarily assigned:

- (a) clinicopathological stage 1A melanoma?
- (b) clinicopathological stage 1B to 2C melanoma (including, but not limited to, sentinel lymph node biopsy)?
- (c) clinicopathological stage 3 melanoma?
- (d) clinicopathological stage 4 melanoma?

RQ 3.1 What are the most effective surgical and histological excision margins for stage 0 to 2 melanoma?

RQ 4.1 What is the effectiveness of completion lymphadenectomy for micro metastatic nodal disease in stage 3 melanoma?

RQ 4.2 What is the utility of sentinel lymph node biopsy for people with stage 3 melanoma and micro-satellite lesions?

RQ 5.1 What is the most effective systemic and localised anticancer treatment for people with stage 4 (+ unresectable stage 3) melanoma?

RQ 6.1 What is the optimal method, frequency, setting and duration of follow-up for stage I-III melanoma?

RQ 6.2 What is the diagnostic accuracy of body imaging for re-staging during the follow-up of people melanoma?

RQ 6.3 Should brain imaging be included for people with melanoma who are undergoing body imaging as part of follow-up, and who have no neurological signs or symptoms?

RQ 6.4 What is the effectiveness of body imaging for the follow-up of people with stage 4 (and unresectable stage 3) melanoma after concluding treatment, including the optimal frequency and duration?